11.4. Corticosteroids and other anti-inflammatory preparations
Macular Oedema: Restricted to specialist use in adult patients with macular oedema following central retinal vein occlusion (CRVO) and in patients with branch retinal vein occlusion (BRVO) who are not clinically suitable for laser treatment including patients with dense macular haemorrhage or patients who have received and failed on previous laser treatment in accordance with local protocol.
Diabetic Macular Oedema: Use in the treatment of adults with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy, is restricted to specialist use only.
Non-infectious Uveitis: Use for the treatment of non-infectious uveitis is restricted to specialist use in accordance with NICE TA460.
Restricted to specialist use for the following:
- The treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies, only in patients in whom the affected eye is pseudophakic (has an artificial lens after cataract surgery) and retreatment would take place only if the patient had previously responded to treatment with fluocinolone acetonide and subsequently best corrected visual acuity had deteriorated to less than 20/32.
- The prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
11.4.2. Other anti-inflammatory preparations
The 2% eye drops are the first-line anti-inflammatory preparation.
Prevention and treatment of inflammation, and prevention of infection associated with cataract surgery in adults.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.